The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. ⋯ A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
-
Randomized Controlled Trial Multicenter Study
Higher or Lower Hemoglobin Transfusion Thresholds for Preterm Infants.
Limited data suggest that higher hemoglobin thresholds for red-cell transfusions may reduce the risk of cognitive delay among extremely-low-birth-weight infants with anemia. ⋯ In extremely-low-birth-weight infants, a higher hemoglobin threshold for red-cell transfusion did not improve survival without neurodevelopmental impairment at 22 to 26 months of age, corrected for prematurity. (Funded by the National Heart, Lung, and Blood Institute and others; TOP ClinicalTrials.gov number, NCT01702805.).
-
Editorial Comment
Hiding in Plain Sight - Somatic Mutation in Human Disease.
-
Editorial Comment
SARS-CoV-2 Vaccination - An Ounce (Actually, Much Less) of Prevention.